Nuwellis (NASDAQ:NUWE) Releases Earnings Results, Beats Estimates By $2.62 EPS

Nuwellis (NASDAQ:NUWE) posted its earnings results on Monday. The company reported $1.74 EPS for the quarter, topping the consensus estimate of ($0.88) by $2.62, Zacks reports. Nuwellis had a negative return on equity of 1,716.60% and a negative net margin of 232.24%. The business had revenue of $2.37 million during the quarter, compared to the consensus estimate of $2.40 million. During the same quarter last year, the company earned ($63.29) EPS.

Nuwellis Price Performance

Shares of NASDAQ:NUWE traded down $0.12 during midday trading on Tuesday, reaching $1.93. The company’s stock had a trading volume of 1,048,744 shares, compared to its average volume of 948,617. The business’s fifty day simple moving average is $1.51 and its 200-day simple moving average is $3.94. The company has a market capitalization of $3.60 million, a P/E ratio of -0.01 and a beta of 0.36. Nuwellis has a fifty-two week low of $1.00 and a fifty-two week high of $31.15.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on NUWE shares. Roth Capital upgraded shares of Nuwellis to a “strong-buy” rating in a research note on Monday, July 29th. Roth Mkm reaffirmed a “buy” rating and set a $17.00 price objective on shares of Nuwellis in a research note on Tuesday, August 13th.

About Nuwellis

Nuwellis, Inc, a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter.